Abstract
This research examines the European Cardiovascular Market in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure in the major markets, the revenue forecasts and growth rates and strategic recommendations.
Table of Contents
1. EXECUTIVE SUMMARY
Overview
- 1. Overview of the European Cardiovascular Drugs Market
2. GLOSSARY OF TERMS
List of Terms
- 1. Abbreviations
3. INTRODUCTION
Disease State Overview
- 1. Disease Description and Risk Factors
- 2. Types of Heart Disease
- 3. Disease Management and Current Treatments
Research Methodology
- 1. Research Methodology for the European Cardiovascular Drugs Market
- 2. Assumptions and Limitations
4. INDUSTRY CHALLENGES
Challenges and Issues
- 1. Challenges Facing the European Cardiovascular Drugs Market
5. MARKET ENGINEERING RESEARCH FOR WORLD CARDIOVASCULAR DRUGS MARKET
World Cardiovascular Drugs Market
- 1. Introduction
- 2. Measurement Analysis
- 3. Revenue Forecasts
- 4. Trends by Geographic Regions
- 5. Segment Analysis
6. MARKET ENGINEERING RESEARCH FOR EUROPEAN CARDIOVASCULAR DRUGS MARKET
European Cardiovascular Drugs Market
- 1. Introduction and Market Segmentation
- 2. Measurements Analysis
- 3. Key Market Drivers
- 4. Key Market Restraints
- 5. Revenue Forecasts
- 6. Segment-wise Analysis
7. CARDIOVASCULAR DRUGS MARKET IN THE UNITED KINGDOM
Research
- 1. Market Overview
- 2. Revenue Forecasts
8. CARDIOVASCULAR DRUGS MARKET IN GERMANY
Research
- 1. Market Overview
- 2. Revenue Forecasts
9. CARDIOVASCULAR DRUGS MARKET IN FRANCE
Research
- 1. Market Overview
- 2. Revenue Forecasts
10. CARDIOVASCULAR DRUGS MARKET IN ITALY
Research
- 1. Market Overview
- 2. Revenue Forecasts
11. CARDIOVASCULAR DRUGS MARKET IN SPAIN
Research
- 1. Market Overview
- 2. Revenue Forecasts
12. PORTFOLIO ANALYSIS
Company Profiles and Product Pipeline
- 1. AstraZeneca
- 2. Bristol-Myers Squibb
- 3. Merck & Co. Inc
- 4. Novartis
- 5. Pfizer
- 6. Sanofi-Aventis
13. STRATEGIC RECOMMENDATIONS
Recommendations
- 1. Strategic Recommendations for the European Cardiovascular Drugs Market
14. DATABASE OF KEY INDUSTRY PARTICIPANTS
Key Industry Participants
- 1. Major Participants
15. DECISION SUPPORT DATABASES
Cardiovascular Diseases
- 1. Cardiovascular Prevalence
- 2. Percent of Cardiovascular Disease Prevalence
- 3. Prevalence of Hypertension
- 4. Prevalence of Hypertension as Percentage of Population
- 5. Incidence of Myocardial Infarction
- 6. Incidence of Stroke
- 7. Mortality due to Coronary Heart Disease
- 8. Mortality due to Circulatory Disease
- 9. Mortality due to Chronic Rheumatic Heart Disease
- 10. Heart Attack Mortality
- 11. Mortality due to Hypertensive Diseases
